P039 The EGFR-inhibitor erlotinib exhibits various off-target effects in MDS and AML

Simone Boehrer; L. Adàs; Theodore P. Braun; Lorenzo Galluzzi; Joël Grosjean; Claire Fabre; Stéphane de Botton; Claude Gardin; Pierre Fenaux; Guido Guido Kroemer

doi:10.1016/s0145-2126(07)70109-1

Related publications

Article2007

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study

Simone Boehrer, Lionel Adès, Thorsten Braun, Lorenzo Galluzzi, J. Grosjean, Claire Fabre, Geneviève Roux, Claude Gardin, Antoine Martin, Stéphane de Botton, Pierre Fenaux, Guido Guido Kroemer

Article2007

The EGFR-Inhibitor Erlotinib Induces Differentiation, Cell Cycle Arrest and Apoptosis in EGFR-Negative Cells of MDS and AML.

Simone Boehrer, Lionel Adès, Thorsten Braun, Lorenzo Galluzzi, J. Grosjean, Claire Fabre, Geneviève Roux, Claude Gardin, Antoine Martin, Stéphane de Botton, Pierre Fenaux, Guido Guido Kroemer

Article2011

Potentiation of Apoptosis in MDS/AML by Combination of Azacitidine and the EGFR-Tyrosine Kinase Inhibitor (TKI) erlotinib

Élodie Lainey, Marie Sébert, Cyrielle Bouteloup, Carole Leroy, Sylvain Thépot, Maximilien Tailler, Lionel Adès, Claude Gardin, Guido Guido Kroemer, Pierre Fenaux, Simone Boehrer

Article2009

Increased Proliferation Induced by Constitutive Activation of the Src-Kinase Lyn and Aberrant mTOR Signaling in AML Is Abrogated by the EGFR-Inhibitor Erlotinib.

Simone Boehrer, Lorenzo Galluzzi, Lionel Adès, Celine Fouassier, Claude Gardin, Pierre Fenaux, Guido Guido Kroemer

Article2007

P057 Abrogation of the DNA-damage response in AML versus MDS cell lines

Simone Boehrer, Lionel Adès, Thorsten Braun, J. Grosjean, Catherine Fabre, Pierre Fenaux, Guido Guido Kroemer

P039 The EGFR-inhibitor erlotinib exhibits various off-target effects in MDS and AML

Discussion(0)

Related publications

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study

The EGFR-Inhibitor Erlotinib Induces Differentiation, Cell Cycle Arrest and Apoptosis in EGFR-Negative Cells of MDS and AML.

Potentiation of Apoptosis in MDS/AML by Combination of Azacitidine and the EGFR-Tyrosine Kinase Inhibitor (TKI) erlotinib

Increased Proliferation Induced by Constitutive Activation of the Src-Kinase Lyn and Aberrant mTOR Signaling in AML Is Abrogated by the EGFR-Inhibitor Erlotinib.

P057 Abrogation of the DNA-damage response in AML versus MDS cell lines